On Sep 9, 2021 LEXEO Therapeutics closed a Series B round and raised $100,000,000 from Alexandria Venture Investments, CAM Capital, D1 Capital Partners, Eventide Asset Management, Gray’s Creek Capital Partners, Intus Capital, Janus Henderson Investors, Laurion Capital Management, Longitude Capital, Lundbeckfonden Ventures, Omega Funds, PBM Capital Group, Verition Fund Management, Woodline Partners, featuring lead investors D1 Capital Partners, Eventide Asset Management.

About the company: LEXEO Therapeutics is located at United States, North America.
“LEXEO Therapeutics is a New York City based clinical stage gene therapy biotechnology company with a focus on hereditary and acquired diseases of high unmet need. ”

Company website: http://www.lexeotx.com